TALAPRO-2__Supplementary_Material.docx (76.65 kB)

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. Supplementary Material

figure

posted on 2022-01-26, 10:22 authored by Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

Supplementary Figure 1- Study locations of TALAPRO-2

Supplementary Methods - DDR alteration analysis

Infographic – Summary of the TALAPRO-2 study

Funding

Pfizer

History

Usage metrics

Future Oncology

Keywords

androgen receptor enzalutamide DDR PARP inhibitor talazoparib mCRPC Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0